Gossamer Bio, Inc.

GOSS

Gossamer Bio, Inc.

GOSS

Insider Sentiment (TTM):

Last Purchase:2025-08-19Last Sale:2024-06-24Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:157,689,299Shares Outstanding:234,137,364Institutional Ownership Pct.:67.35%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	41	41	38	9	26	29	46	28	87	39	32	83
Marketable Securities Current	16	58	99	171	187	229	248	299	268	206	264	246
Accounts Receivable Net Current	6	9	12	9	8	7	5	7	4	-	0	-
Prepaid Expense And Other Assets Current	10	16	18	15	15	11	10	11	13	11	10	13
Assets Current	73	125	168	204	236	275	310	344	371	255	307	341
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	1	1	2	2
Operating Lease Right Of Use Asset	4	4	4	4	5	5	5	6	2	2	3	4
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	1	1	1
Assets	77	129	172	209	241	281	315	351	373	259	312	348
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	6	11	6	1	2	3	2	3	1	3	6	1
Contract With Customer Liability Current	7	9	20	24	23	18	17	20	17	-	0	-
Long Term Debt Current	-	-	-	-	-	-	0	0	0	10	12	12
Accrued Liabilities Current	18	20	16	19	13	12	15	17	16	15	27	17
Liabilities Current	138	57	63	62	54	48	45	51	45	36	52	42
Operating Lease Liability Noncurrent	3	3	3	4	4	4	4	5	0	0	0	1
Contract With Customer Liability Noncurrent	30	32	30	27	31	37	39	44	50	-	0	-
Long Term Debt Noncurrent	-	-	-	-	-	-	0	0	0	0	1	4
Liabilities	171	290	295	291	287	287	286	297	292	233	249	243
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,378	1,328	1,321	1,314	1,302	1,300	1,297	1,292	1,287	1,281	1,275	1,269
Retained Earnings Accumulated Deficit	-1,469	-1,486	-1,439	-1,392	-1,343	-1,305	-1,269	-1,236	-1,205	-1,254	-1,212	-1,164
Accumulated Other Comprehensive Income Loss Net Of…	-4	-4	-5	-5	-5	-1	1	-2	-1	-1	-0	-1
Stockholders Equity	-94	-161	-123	-82	-46	-6	29	54	82	27	63	105
Liabilities And Stockholders Equity	77	129	172	209	241	281	315	351	373	259	312	348
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	700	700	700	700	700	700	700	700	700	700	700	700
Common Stock Shares Issued	489	235	234	231	227	227	227	227	226	226	225	225
Shares Outstanding	489	235	234	231	227	227	227	227	226	226	225	225

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-48.53%	-49.12%	-50.00%	-	-	-	-	-	-	-	-	-
2025	26.67%	18.10%	90.48%	14.35%	25.00%	14.81%	40.93%	36.29%	13.92%	-13.14%	-30.72%	-62.92%
2024	-19.40%	23.09%	53.01%	14.47%	34.59%	9.94%	-21.31%	-3.61%	4.85%	-38.46%	-9.23%	-14.62%
2023	-	-	-	-	-	-	53.82%	66.00%	45.45%	-18.62%	-53.93%	-57.24%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.53	2.20	2.64	3.28	4.40	5.71	6.88	6.74	8.21	7.13	5.94	8.07
Quick Ratio	0.46	1.92	2.35	3.05	4.11	5.49	6.66	6.53	7.93	6.82	5.74	7.77
Working Capital	-65.06M	68.03M	104.21M	141.87M	182.30M	227.25M	264.88M	293.18M	325.72M	219.45M	254.92M	299.17M
Leverage & Debt
Debt to Equity	-1.82	-1.80	-2.40	-3.54	-6.23	-45.89	9.69	5.48	3.58	8.71	3.97	2.33
Interest Coverage TTM	-15.16	-16.26	-15.54	-14.65	-13.28	-4.92	-5.20	-6.06	-6.29	-13.53	-13.60	-13.77
Debt Ratio	2.22	2.25	1.71	1.39	1.19	1.02	0.91	0.85	0.78	0.90	0.80	0.70
Efficiency & Turnover
Asset Turnover TTM	0.40	0.32	0.24	0.16	0.13	0.46	0.37	0.30	0.35	0.00	0.00	0.00
Days Sales Outstanding TTM	39.53	44.17	54.93	65.59	50.84	19.29	16.99	22.83	13.82	-	-	-
Receivables Turnover TTM	9.23	8.26	6.65	5.57	7.18	18.93	21.49	15.99	26.41	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.38	-0.77	-0.75	-0.68	-0.61	-0.23	-0.25	-0.32	-0.34	-0.76	-1.18	-0.97
Free Cash Flow Per Share TTM	-0.51	-0.73	-0.75	-0.52	-0.50	0.04	-0.02	-0.01	-0.02	-0.70	-1.04	-0.90
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-262.91%	-273.26%	-292.54%	-365.07%	-361.91%	-43.96%	-52.24%	-69.14%	-82.83%	-	-	-
Net Profit Margin TTM	-198.22%	-275.73%	-291.93%	-354.50%	-344.81%	-41.13%	-49.28%	-68.03%	-84.36%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	57.01%	-47.49%	-49.12%	-58.17%	-58.02%	-	-	-	-	-	-	-
Net Income Growth (1Y)	-9.74%	252.07%	201.39%	117.96%	71.60%	-70.31%	-68.56%	-61.77%	-60.90%	-21.82%	-21.61%	-18.47%
EPS Growth (1Y)	-35.90%	241.07%	198.37%	116.40%	70.81%	-70.45%	-78.79%	-67.43%	-83.50%	-67.14%	-56.56%	-61.46%
Valuation Metrics
P/E TTM	-0.42	-0.43	-4.16	-3.84	-2.01	-4.87	-3.62	-3.11	-2.52	-1.54	-0.77	-0.86
P/B TTM	-0.56	-0.48	-5.77	-7.28	-6.06	-39.92	6.94	4.12	2.50	9.97	2.22	1.54
P/S TTM	0.84	1.18	12.14	13.61	6.95	2.00	1.78	2.12	2.13	-	-	-
Market Cap	52.80M	77.03M	708.41M	599.59M	279.55M	249.50M	204.74M	223.18M	203.83M	266.37M	139.34M	160.67M
Enterprise Value	11.65M	36.00M	670.68M	590.66M	253.24M	220.48M	158.66M	194.71M	116.95M	237.09M	119.66M	93.31M
Calculated Values
Free Cash Flow TTM	-163.66M	-170.32M	-171.35M	-118.76M	-114.63M	9.08M	-3.47M	-1.41M	-3.87M	-158.47M	-159.16M	-173.57M
Net Debt	-41.15M	-41.03M	-37.73M	-8.93M	-26.31M	-29.02M	-46.07M	-28.46M	-86.88M	-29.27M	-19.68M	-67.36M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-08-19Purchase

Owner: Milligan, Sandra

Title: -

Shares: 26,050

Price/Share: $1.92

Value: $50,016.00

Shares Owned: 58,050

Relationship: Director

Ownership: Direct

2024-06-24Sale

Owner: Aranda, Richard

Title: Chief Medical Officer

Shares: 1,908

Price/Share: $0.66

Value: $1,259.28

Shares Owned: 196,891

Relationship: Officer

Ownership: Direct

2024-06-21Purchase

Owner: Hasnain, Faheem

Title: President & CEO

Shares: 372,000

Price/Share: $0.67

Value: $249,240.00

Shares Owned: 5,408,073

Relationship: Director,Officer

Ownership: Indirect

2024-06-18Purchase

Owner: Giraudo, Bryan

Title: COO/CFO

Shares: 100,000

Price/Share: $0.59

Value: $59,000.00

Shares Owned: 480,010

Relationship: Officer

Ownership: Indirect

2024-06-17Purchase

Owner: Smith, Robert Paul Jr

Title: Chief Commercial Officer

Shares: 25,000

Price/Share: $0.60

Value: $15,000.00

Shares Owned: 25,000

Relationship: Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-08-19	Milligan, Sandra	Director	-	Direct	Purchase	26,050	1.92	$50,016.00	58,050	4
2024-06-24	Aranda, Richard	Officer	Chief Medical Officer	Direct	Sale	1,908	0.66	$1,259.28	196,891	4
2024-06-21	Hasnain, Faheem	Director,Officer	President & CEO	Indirect	Purchase	372,000	0.67	$249,240.00	5,408,073	4
2024-06-18	Giraudo, Bryan	Officer	COO/CFO	Indirect	Purchase	100,000	0.59	$59,000.00	480,010	4
2024-06-17	Smith, Robert Paul Jr	Officer	Chief Commercial Officer	Indirect	Purchase	25,000	0.60	$15,000.00	25,000	4
2024-03-27	Christian, Waage	Officer	EVP, Tech Ops and Admin	Direct	Sale	6,430	1.16	$7,458.80	585,934	4
2024-03-27	Hasnain, Faheem	Director,Officer	President & CEO	Direct	Sale	23,172	1.16	$26,879.52	120,293	4
2024-03-27	Giraudo, Bryan	Officer	COO/CFO	Direct	Sale	6,430	1.16	$7,458.80	92,737	4
2024-03-18	Peterson, Caryn	Officer	EVP, Regulatory Affairs	Direct	Sale	4,018	1.33	$5,343.94	49,833	4
2024-03-18	Aranda, Richard	Officer	Chief Medical Officer	Direct	Sale	4,018	1.33	$5,343.94	198,799	4
2023-11-15	Milligan, Sandra	Director	-	Indirect	Purchase	32,000	0.79	$25,280.00	32,000	4
2023-11-13	Giraudo, Bryan	Officer	COO/CFO	Indirect	Purchase	200,000	0.56	$112,000.00	380,010	4
2023-06-22	Aranda, Richard	Officer	Chief Medical Officer	Direct	Sale	1,814	1.29	$2,340.06	197,574	4
2023-04-04	Giraudo, Bryan	Officer	COO/CFO	Indirect	Purchase	55,000	1.02	$56,100.00	125,990	4
2023-03-22	Hasnain, Faheem	Director,Officer	President & CEO	Indirect	Purchase	440,500	1.14	$502,170.00	4,495,897	4
2023-03-20	Christian, Waage	Officer	EVP, Tech Ops and Admin	Indirect	Purchase	18,500	1.20	$22,200.00	32,388	4
2023-03-20	Giraudo, Bryan	Officer	COO/CFO	Indirect	Purchase	50,000	0.97	$48,500.00	70,990	4
2023-03-16	Peterson, Caryn	Officer	EVP, Regulatory Affairs	Direct	Sale	7,564	1.10	$8,320.40	53,851	4
2023-03-16	Carter, Laura	Officer	Chief Scientific Officer	Direct	Sale	6,029	1.10	$6,631.90	76,263	4
2023-03-16	Aranda, Richard	Officer	Chief Medical Officer	Direct	Sale	7,563	1.10	$8,319.30	199,388	4
2022-10-24	Carter, Laura	Officer	Chief Scientific Officer	Direct	Sale	4,876	12.07	$58,853.32	82,292	4/A
2022-10-24	Aranda, Richard	Officer	Chief Medical Officer	Direct	Sale	4,757	12.07	$57,416.99	205,430	4
2022-10-24	Peterson, Caryn	Officer	EVP, Regulatory Affairs	Direct	Sale	4,757	12.07	$57,416.99	61,415	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

67.35%

Inst. Shares: 157,689,299

Shares Outstanding: 234,137,364

2025-12-31

78.27%

Inst. Shares: 178,859,007

Shares Outstanding: 228,519,130

2025-09-30

76.57%

Inst. Shares: 174,576,206

Shares Outstanding: 227,981,475

2025-06-30

74.21%

Inst. Shares: 168,655,778

Shares Outstanding: 227,275,466

2025-03-31

63.31%

Inst. Shares: 143,589,161

Shares Outstanding: 226,818,051

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	157,689,299	234,137,364	67.35%
2025-12-31	178,859,007	228,519,130	78.27%
2025-09-30	174,576,206	227,981,475	76.57%
2025-06-30	168,655,778	227,275,466	74.21%
2025-03-31	143,589,161	226,818,051	63.31%
2024-12-31	165,105,518	226,228,016	72.98%
2024-09-30	164,197,126	226,346,058	72.54%
2024-06-30	172,822,410	226,221,202	76.40%
2024-03-31	190,599,103	225,735,236	84.43%
2023-12-31	188,035,320	152,621,669	123.20%
2023-09-30	197,577,689	192,883,209	102.43%
2023-06-30	50,688,345	95,446,929	53.11%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Gossamer Bio, Inc. (GOSS) — SEC Financial Statements & Analysis

Gossamer Bio, Inc. (GOSS) is a pharmaceutical preparations company, incorporated in DE. Gossamer Bio, Inc. trades on Nasdaq as: GOSS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Gossamer Bio, Inc. reported a 57.01% year-over-year revenue growth, a Debt-to-Equity ratio of -1.82x, a Price-to-Sales (P/S) ratio of 0.84x (TTM), a Price-to-Book (P/B) ratio of -0.56x (TTM), at a market cap of $52.80M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 57.01%
Debt To Equity: -1.82x
P/S TTM: 0.84x
P/B TTM: -0.56x
Market Cap: $52.80M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Gossamer Bio, Inc. in?

Gossamer Bio, Inc. (GOSS) operates in the Pharmaceutical Preparations industry.

What is GOSS's market cap?

Gossamer Bio, Inc. (GOSS) has a market capitalization of $52.80M as of 2026-06-30.

What exchange does GOSS trade on?

Gossamer Bio, Inc. (GOSS) trades on the Nasdaq.

Where is Gossamer Bio, Inc. incorporated?

Gossamer Bio, Inc. is incorporated in DE.

Gossamer Bio, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Gossamer Bio, Inc. (GOSS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Gossamer Bio, Inc. (GOSS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.